October 1, 2009
By:G. Steven Burrill
Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.
 |
July 1, 2009
By:G. Steven Burrill
Although the markets closed on a positive note in May, it will still take many more months before biotech starts on the road to full recovery.
|
April 1, 2009
By:G. Steven Burrill
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
|
January 1, 2009
By:G. Steven Burrill
Small biotechs were forced to restructure and downsize.
|
December 1, 2008
By:G. Steven Burrill
The meltdown in the financial markets represents a sea change in the world of financing that will continue to affect the flow of much needed capital into the sector for the foreseeable future.
|
October 1, 2008
By:G. Steven Burrill
The biotech industry's year-to-date report card contains good grades despite the turbulent economic climate.
|
June 1, 2008
By:G. Steven Burrill
Following the market crisis of the first quarter of 2008, biotech IPOs and financing are down, but partnering continues, and mergers and acquisitions (M&As) remain hot.
|
March 1, 2008
By:G. Steven Burrill
Despite the rising fears about a slowing economy, the biotech industry will continue to maintain its momentum this year.
|
| 
